Rifapentine structure
|
Common Name | Rifapentine | ||
---|---|---|---|---|
CAS Number | 61379-65-5 | Molecular Weight | 877.031 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 969.3±65.0 °C at 760 mmHg | |
Molecular Formula | C47H64N4O12 | Melting Point | 179-180ºC | |
MSDS | Chinese USA | Flash Point | 540.0±34.3 °C | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of RifapentineRifapentine (Priftin; DL 473) is an antibiotic compound used in the treatment of tuberculosis.Target: AntibacterialRifapentine inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. A review of alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self -administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity . However the rates of treatment-limiting adverse events were higher in the rifapentine-isoniazid regimen [1]. |
Name | rifapentine |
---|---|
Synonym | More Synonyms |
Description | Rifapentine (Priftin; DL 473) is an antibiotic compound used in the treatment of tuberculosis.Target: AntibacterialRifapentine inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. A review of alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self -administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity . However the rates of treatment-limiting adverse events were higher in the rifapentine-isoniazid regimen [1]. |
---|---|
Related Catalog | |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 969.3±65.0 °C at 760 mmHg |
Melting Point | 179-180ºC |
Molecular Formula | C47H64N4O12 |
Molecular Weight | 877.031 |
Flash Point | 540.0±34.3 °C |
Exact Mass | 876.452087 |
PSA | 216.66000 |
LogP | 2.58 |
Vapour Pressure | 0.0±0.3 mmHg at 25°C |
Index of Refraction | 1.625 |
Storage condition | -20°C Freezer |
Water Solubility | methanol: soluble2mg/mL, clear, red to red-brown |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Hazard Codes | Xi |
Risk Phrases | 36/37/38 |
Safety Phrases | 26 |
RIDADR | NONH for all modes of transport |
RTECS | JQ0902000 |
HS Code | 2941903000 |
HS Code | 2941903000 |
---|
Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.
Antimicrob. Agents Chemother. 58(6) , 3168-76, (2014) Predicting drug-drug interactions (DDIs) related to cytochrome P450 (CYP), such as CYP3A4 and one of the major drug transporters, P-glycoprotein (P-gp), is crucial in the development of future chemoth... |
|
Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Mol. Pharm. 12 , 2594-603, (2015) Colistin has been increasingly used for the treatment of respiratory infections caused by Gram-negative bacteria. Unfortunately parenteral administration of colistin can cause severe adverse effects. ... |
|
Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.
Int. J. Infect. Dis. 25 , 82-7, (2014) A Mycobacterium parascrofulaceum strain was isolated from a pneumonia patient-the first such reported case from China. The bacteriological characteristics of the strain were determined.Species identif... |
rifamycin-S |
Rifamycin-B-tripropyl-hydrazid |
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-{[(4-Cyclopentyl-1-piperazinyl)imino]methyl}-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracy ;clo[23.3.1.1.0]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl acetate |
Rifapentine |
rifamycin-B tripropylhydrazide |
2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-8-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)- |
EINECS 262-743-9 |